InterMune files $175 million debt, stock shelf

By Angela McDaniels

Seattle, Dec. 28 - InterMune, Inc. registered to sell up to $175 million of securities in an S-3 filing with the Securities and Exchange Commission on Thursday.

Covered by the shelf are debt securities, common stock, preferred stock and warrants to purchase debt securities, common stock or preferred stock. Debt securities and preferred stock may be structured as convertibles.

Proceeds will be used for general corporate purposes, which may include funding research and development, working capital, debt reduction, capital expenditures and acquisitions or investments in complementary businesses, products or technologies.

The shelf also includes a secondary offering of up to 7,357,549 shares of common stock at a total maximum offering price of $221,535,800 to be sold by current stockholder Warburg, Pincus Equity Partners LP and its affiliates.

InterMune is a Brisbane, Calif., biotechnology company developing therapies in pulmonology and hepatology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.